The Inflation Reduction Act includes an exemption for orphan drugs for a single indication, but experts say this is far from ...

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

The approach could enable 30-minute testing for a heart condition that is newly treatable following recent drug approvals.

Issi covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Ultragenyx Pharmaceutical, and Ascendis Pharma. In addition to RBC Capital, Alnylam Pharma also received a Buy from J.P.

GlobalData estimates that vutrisiran’s entrance into the ATTR-wt market will change the treatment paradigm.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 13 Biotech Stocks with Huge Upside Potential. It declared on June 9 ...

The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce ...

ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.

Alnylam Pharmaceuticals, Inc.ALNY announced that the European Commission (EC) has approved a label expansion of its RNAi therapeutic Amvuttra.. The EC has now approved Amvuttra for the treatment ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the European Commission (EC) to treat adults with transthyretin amyloid cardiomyopathy (ATTR-CM), a potentially fatal disease of the ...